Drug Profile
Research programme: BACE1 protein inhibitors - Zoegene/Fujitsu
Latest Information Update: 01 Dec 2010
Price :
$50
*
At a glance
- Originator Fujitsu; Zoegene Corporation
- Developer Fujitsu; Molecuence Corporation
- Class
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 06 Feb 2007 Discontinued - Preclinical for Alzheimer's disease in Japan (unspecified route)
- 25 Apr 2005 Preclinical trials in Alzheimer's disease in Japan (unspecified route)